PATENT CLAIM ANALYSIS

Application Number: 16376216
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["424", "085700"]

Abstract:
Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer

Claim (Index 16):
The fusion protein of  claim 1 , comprising the amino acid sequence of SEQ ID NO: 4 [MR1-1 IFN\u03b1 2-1b E59A M149A].

Metadata:
- Claim Count in Document: 24.0
- Percentile: 100.0
- Lexical Diversity: 1.36585
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15307646', '12985122', '15359456', '12541062', '12610204']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7035475110395802
- 35 USC 102 Novelty (BERT): 0.6807800129385344
- Combined Prediction Score: 0.7012707612294756
- Mean Citation Score: 379.304904
- Max Citation Score: 669.4451
- Similarity Product: 633.1821284271241

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test